Navigation Links
BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update
Date:2/6/2009

onths ended December 31, 2007.

Net income for the quarter ended December 31, 2008, was $10.1 million, or $0.26 per share, compared to a net loss for the quarter ended December 31, 2007, of $2.3 million, or $0.06 per share.

Year End 2008 Financial Results

Collaborative and other R&D revenues were $56.6 million for the year ended December 31, 2008, compared to $71.2 million for the year ended December 31, 2007. This decrease was partially driven by a reduction in revenue from the contract with HHS for the development of peramivir, plus a $4.9 million reserve recorded by the Company during the second quarter of 2008 for amounts that were previously expected to be received from HHS related to costs incurred in the Phase 3 program of intramuscular (i.m.) peramivir for outpatient influenza. The Company initiated this program and voluntarily discontinued it following a decision to pursue higher doses in the ongoing Phase 2 study. Reimbursement of these costs is under discussion with HHS. Further contributing to the decrease in collaborative and other R&D revenues from 2007 to 2008 was the prior year receipt of a $7.0 million milestone payment from Shionogi. This was offset by the recognition of $26.5 million of previously deferred revenue related to the termination of the Company's collaboration with Roche.

R&D expenses were $73.3 million for the year ended December 31, 2008, compared to $94.1 million for the year ended December 31, 2007. The decrease in R&D expenses was due to a reduction in the clinical development costs and toxicology costs associated with the peramivir program and a reduction in manufacturing costs associated with both the peramivir and Forodesine HCl programs. These reductions were offset by an increase in the Company's clinical development costs for Forodesine HCl, the recognition of $8.2 million of previously deferred expense related to the terminatio
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... to biotechnology firms has revealed early bottlenecks on ... the researchers suggest that better communication of basic ... to faster commercialization down the road. , Biopharmaceutical ... university laboratories and licensed to biotechnology firms. Bottlenecks ... a high failure rate. But a new study ...
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group finds that the vascular ... Russia , India and ... 2013, roughly equal to the size of the United ... market will experience much faster growth as a result of strong ... Other key findings from Decision Resources Group,s coverage of the ...
(Date:8/20/2014)... in your ear could improve the health of your ... University of Leeds used a standard TENS machine like ... pulses to the tragus, the small raised flap at ... the ear canal. , The stimulation changed the influence ... the nervous signals that can drive failing hearts too ...
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 Research and ... Culture Supplies - Global Strategic Business Report" report to their ... Cell and Tissue Culture Supplies in US$ Thousands by the following ... separate comprehensive analytics for the US, Canada , ... Asia-Pacific , and Latin America . ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3'Tickling' your ear could be good for your heart 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2
... - For Effective ... EMBASE(R), Elsevier,s biomedical and pharmaceutical ... with QUOSA(TM) to enable,mutual customers to download and manage ... established EMBASE.com channel in QUOSA Information,Manager. , ...
... WAYNE, Pa., Nov. 28 Encorium Group, Inc.,(Nasdaq: ... organization,(CRO) conducting studies in over 30 countries for many ... that on November,21, 2008, it received a letter from ... 10-Q for the quarterly period ended September 30, 2008 ...
... SAN DIMAS, Calif., Nov. 28 Why Humans ... Bill Sardi, co-founder and formulator of Longevinex(R) (long-jev-in-ex), a nutriceutical product ... To view the Multimedia News Release, go to: , ... The film presents the " overmineralization " theory of aging ...
Cached Biology Technology:Elsevier's EMBASE.com Partners With QUOSA 2Elsevier's EMBASE.com Partners With QUOSA 3Elsevier's EMBASE.com Partners With QUOSA 4Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing 2Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing 3Video: 8-Minute Film Documentary Explores Why Humans Age 2
(Date:8/20/2014)... Health has awarded the Oklahoma Medical Research Foundation a ... anthrax and the bacteria,s effects on humans. , ... his colleagues have studied the human immune response to ... Human Immunology. The original funding came soon after anthrax-laced ... of the terrorist attacks of Sept. 11, 2001. ...
(Date:8/20/2014)... the past few years, Virginia Tech,s Wu Feng has ... grant from the "Computing in the Cloud" program, and ... $6 million award from the Air Force on "big ... NSF and the National Institutes of Health on "big ... together the "parallel computing" aspects from each grant, he ...
(Date:8/20/2014)... Carolina State University researchers have developed methods for electronically ... the electrical signals moths use to control those muscles. ... remotely-controlled moths, or "biobots," for use in emergency response. ... whether we can control the movement of moths for ... says Dr. Alper Bozkurt, an assistant professor of electrical ...
Breaking Biology News(10 mins):$14.5 million grant awarded to continue anthrax studies 2The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Research paves way for development of cyborg moth 'biobots' 2
... EAST LANSING, Mich. -- Time marches on, ... of wildlife habitat now can monitor changes over ... and projecting future changes are essential for sustainable ... wildlife habitat," said Jianguo "Jack" Liu, Rachel Carson ...
... in The FASEB Journal ( http://www.faseb.org ) suggests that pregnant ... babies who are likely to become junk food junkies themselves. ... the high fat and high sugar diet leads to changes ... only does this offer insight into the ever-increasing rate of ...
... 23, 2011 -- Structural studies of some of ... way for new generations of biologically inspired solar ... St. Louis and the Department of Energy,s Oak ... analyze the structure of chlorosomes in green photosynthetic ...
Cached Biology News:'Junk food' moms have 'junk food' babies 2Neutron analysis yields insight into bacteria for solar energy 2
Mouse polyclonal antibody to PRDM2 - PR domain containing 2, with ZNF domain...
Anti Human S14G-Humanin Polyclonal Antibody...
... familiar interface for data capture, recording, ... transition from paper to this powerful ... contains an integrated LIMS, notary service, ... These functions allow LABTrack to achieve ...
High voltage electrophoresis power supply...
Biology Products: